Premium
Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention‐deficit/hyperactivity disorder: A pilot study
Author(s) -
Rohde Luis A.,
Roman Tatiana,
Szobot Claudia,
Cunha Renato D.,
Hutz Mara H.,
Biederman Joseph
Publication year - 2003
Publication title -
synapse
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 106
eISSN - 1098-2396
pISSN - 0887-4476
DOI - 10.1002/syn.10186
Subject(s) - methylphenidate , dopamine transporter , attention deficit hyperactivity disorder , cerebral blood flow , dopamine , stimulant , neuroimaging , basal ganglia , pharmacogenetics , psychology , allele , medicine , psychiatry , neuroscience , anesthesia , genotype , genetics , gene , central nervous system , biology , dopaminergic
The homozygosity of the 10‐repeat allele at dopamine transporter gene (DAT1) seems to be associated with a poor response to methylphenidate (MPH) in children with attention‐deficit/hyperactivity disorder (ADHD). This pilot study aimed to simultaneously assess polymorphisms at DAT1, response to MPH, and neuroimaging. Only ADHD children with at least a moderate response to MPH were included. Significantly higher regional cerebral blood flows assessed by single photon emission computerized tomography (SPECT) were detected in medial frontal and left basal ganglia areas in children with homozygosity for the 10‐repeat allele at DAT1 gene ( n = 4) than in children without this genotype ( n = 4) ( P < 0.05). These findings provide a preliminary connection between pharmacogenetics and neurobiological investigations on stimulant treatment of ADHD. Synapse 48:87–89, 2003. © 2003 Wiley‐Liss, Inc.